Complement-mediated acute effects of liposome-encapsulated hemoglobin

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology

Volumn 27, Issue 1, 1999, Pages 23-41

  Szebeni, Janos ^a   Alving, Carl R ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CHEMICAL ACTIVATION; CHEMICAL BONDS; HEMOGLOBIN; LIVING SYSTEMS STUDIES; PHYSIOLOGY;

ANTI-LIPID ANTIBODIES; LIPOSOMES;

BLOOD SUBSTITUTES;

ANTIBODY; BLOOD SUBSTITUTE; COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR; HEMOGLOBIN; LIPOSOME;

COMPLEMENT ACTIVATION; EMERGENCY MEDICINE; ENCAPSULATION; HEART OUTPUT; HUMAN; INJURY; LIPID MEMBRANE; LUNG VASOCONSTRICTION; NONHUMAN; RAT; RESPIRATORY DISTRESS; REVIEW; SWINE;

SUS SCROFA;

EID: 0033001741     PISSN: 10731199     EISSN: None     Source Type: Journal    
DOI: 10.3109/10731199909117481     Document Type: Review

References (64)

1. Anand, N. and Paterson, W. G. Role of nitric oxide in esophageal peristalsis. Am. J. Physiol., 266, G123-G131. (1994)
2. Zuck, T. F. and Riess, J. G. Current status of injectable oxygen carriers. Crit. Rev. Clin. Lab. Sci., 31, 295-324. (1994)
3. Winslow, R. M. In: Artificial Red Cells: Materials, Performances and Clinical Study as Blood Substitutes, (ed. Tsuchida, E.), pp. 117-130. John Wiley & Sons Ltd., New York. (1995)
4. Murray, J. A., Ledlow, A., Launspach, J., Evans, D., Loveday, M. and Conklind, J. L. The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology, 109, 1241-1248. (1995)
5. Rudolph, A. S., Sulpizio, A., Hieble, P., MacDonald, V., Chavez, M. and Feurstein, G. Liposome encapsulation attenuates hemoglobin-induced vasoconstriction in rabbit arterial segments. J. Appl. Physiol., 82, 1826-1835. (1997)
6. Rabinovici, R., Rudolph, A. S. and Feuerstein, G. Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ. Shock, 29, 115-132. (1989)
7. Rudolph, A. S. In: Blood Substitutes. Physiological Basis of Efficacy, (eds. Winslow, R.M., Vandegriff, K.D. & Intaglietta, M.), pp. 98-104. Birkhauser, Boston. (1995)
8. Tsuchida, E. and Takeoka, S. In: Artificial Red Cells, (ed. Tsuchida, E.), pp. 35-64. John Wiley & Sons Ltd., New York. (1995)
9. Szebeni, J., Wassef, N. M., Rudolph, A. S. and Alving, C. R. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim. Biophys. Acta, 1285, 127-130. (1996)
10. Rabinovici, R., Phillips, W. T., Feuerstein, G. and Rudolph, A. S. In: Red Blood Cell Substitutes: Fundamental Principles and Clinical Applications, (eds. Rabinovici, R., Feuerstein, G. & Rudolph, A. S.), pp. 263-287. Marcel Dekker, New York. (1998)
11. Hunt, C. A., Burnette, R. R., Mac.Gregor, R. D., Strubbe, A., Lau, D. T., Taylor, N. and Kawada, H. Synthesis and evaluation of a prototypal artificial red cell. Science, 230, 1165-1168. (1985)
12. 99mTc-labeled liposome-encapsulated hemoglobin in an anesthetized rabbit. Proc. Natl. Acad. Sci. USA, 88, 10976-80. (1991)
13. Phillips, W. T., Rudolph, A. S., Goins, B. and Klipper, R. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studied with a newly developed 99m-technetium liposome label. Biomat. Artif. Cells Immobil. Biotechnol., 20, 757-60. (1992)
14. Rudolph, A. S., Sulpizio, T., Kwasiborski, V., Cliff, R. O., Rabinovici, R. and Feurstein, G. Infusion of liposome-encapsulated hemoglobin in normovolemic primates. Artif. Cells, Blood Subst. Immob. Biotechnol., 24, 415. (1996)
15. Takaori, M. and Fukui, A. Treatment of massive hemorrhage with liposome encapsulated human hemoglobin (NRC) and hydroxyethyl starch (HES) in beagles. Artif. Cells Blood Substit. Immobil. Biotechnol., 24, 643-653. (1996)
16. Usuba, A. and Motoki, R. Effect of liposome encapsulated hemoglobin "neo red cells" on severe hemorrhagic shock. Artif. Cells Blood Substit. Immobil. Biotechnol., 25, 379-392. (1997)
17. Goins, B., Phillips, W. T., Klipper, R. and Rudolph, A. S. Role of complement in rats injected with liposome-encapsulated hemoglobin. J. Surg. Res., 68, 99-105. (1997)
18. Rollwageǹ, F. M., Gafney, W. C., Pacheco, N. D., Davis, T. A., Hickey, T. M., Nielsen, T. B. and Rudolph, A. S. Multiple responses to administration of liposome-encapsulated hemoglobin (LEH): Effects on hematopoiesis and serum IL-6 levels. Exp. Hematol., 24, 429-36. (1996)
19. Djordjevich, L. and Miller, I. F. Synthetic erythrocytes from lipid-encapsulated hemoglobin. Exp. Hematol., 8, 584-592. (1980)
20. Sakaguchi, K., Miyauchi, Y., Suzuki, K. and Takayashi, A. Effects of the neo red cell on the blood coagulation system and the complement system. Jap. J. Artif. Organs, 20, 620-625. (1994)
21. Rabinovici, R., Rudolph, A. S. and Feuerstein, G. Improved biological properties of synthetic distearoyl phosphatidylcholine-based liposome in the conscious rat. Circ. Shock, 30, 207-219. (1990)
22. Rabinovici, R., Rudolph, A. S., Yue, T.-L. and Feuerstein, G. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ. Shock, 31, 431-445. (1990)
23. Rabinovici, R., Rudolph, A. S., Ligler, F. S., Smith III, E. F. and Feuerstein, G. Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ. Shock, 37, 124-33. (1992)
24. Phillips, W. T., Klipper, R., Fresne, D., Rudolph, A. S., Javors, M. and Goins, B. Platelet reactivity with liposome-encapsulated hemoglobin in the rat Exp. Hematol., 25, 1347-1356. (1997)
25. Wassef, N. M., Johnson, S. H., Graeber, G. M., Swartz, G. M., Schultz, C. L., Hailey, J. R., Johnson, A. J., Taylor, D. G., Ridgway, R. L. and Alving, C. R. Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. J. Immunol., 143, 2990-2995. (1989)
26. Szebeni, J., Fontana, J. L., Mongan, P. D., Stahl, G. L., Wassef, N. M., Bunger, R. and Alving, C. R. Hemodynamic changes in pigs induced by liposomes and liposome-encapsulated hemoglobin: The role of complement. Manuscript submitted. (1998)
27. Szebeni, J. The interaction of liposomes with the complement system. Crit. Rev. Ther. Drug Carr. Syst., 15, 57-89. (1998)
28. Szebeni, J., Wassef, N. M., Spielberg, H., Rudolph, A. S. and Alving, C. R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys. Res. Comm., 205, 255-263. (1994)
29. Szebeni, J., Wassef, N. M., Rudolph, A. S. and Alving, C. R. Complement activation by liposome-encapsulated hemoglobin: the role of natural in vitro: the role of endotoxin contamination. Artif. Cells Blood Subs. and Immob. Biotechnol., 23, 355-363. (1995)
30. Szebeni, J., Spielberg, H., Cliff, R. O., Wassef, N. M., Rudolph, A. S. and Alving, C. R. Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin: Inhibition by soluble complement receptor type 1. Art. Cells, Blood Subs. Immob. Biotechnol., 25, 379-392. (1997)
31. Szebeni, J., Wassef, N. M., Hartman, K. R., Rudolph, A. S. and Alving, C. R. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin: Mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion, 37, 150-159. (1997)
32. Hugli, T. E. Structure and function of anaphylatoxins. Spring. Semin. Immunopathol., 7, 193-219. (1984)
33. Marceau, F., Lundberg, C. and Hugli, T. E. Effects of anaphylatoxins on circulation. Immunopharmacol., 14, 67-84. (1987)
34. Szebeni, J., Hauser, H., Eskelson, C. D., Watson, R. R. and Winterhalter, H. K. Interaction of hemoglobin derivatives with liposomes. Membrane cholesterol protects against the changes of hemoglobin. Biochemistry, 27, 6425-6434. (1988)
35. Rabinovici, R., Rudolph, A. S., Ligler, F. S., Yue, T.-L. and Feuerstein, G. Liposome-encapsulated hemoglobin: an oxygen-carrying fluid. Circ. Shock, 32, 1-17. (1990)
36. Chonn, A., Cullis, P. R. and Devine, D. V. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J. Immunol., 146, 4234-4241. (1991)
37. Moore, F. D. J., Austen, K. F. and Fearon, D. T. Antibody restores human alternative complement pathway activation by mouse erythrocytes rendered functionally deficient by pretreatment with pronase. J. Immunol., 128, 1302-1306. (1982)
38. Fries, L. F., Gaither, T. A., Hammer, C. H. and Frank, M. M. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J. Exp. Med., 160, 1640-1655. (1984)
39. Stahl, G. L., Amsterdam, E. A., Symons, J. D. and Longhurst, J. C. Role of thromboxane A2 in cardiovascular response to intracoronary C5a. Circ. Res., 66, 1103-1111. (1990)
40. Stahl, G., Morse, D. S. and Martin, S. L. Eicosanoid production from porcine neutrophils and platelets: differential production with various agonists. Am. J. Physiol., 272, C1821-C1828. (1997)
41. Stahl, G. L., Reenstra, W. R. and Frendl, G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of terminal membrane attack complex. Circ. Res., 76, 575-583. (1995)
42. Salama, A, Hugo, F., Heinrich, D., Hoge, R., Muller, R., Kiefel, V., Mueller-Eckhardt, C. and Bhakdi, S. Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N. Eng. J. Med., 318, 408-414. (1988)
43. 2. J. Cardiovasc. Pharmacol., 26, S120-2. (1995)
44. Yamamoto, S., Burman, H. P., O'Donnell, C. P., Cahill, P. A. and Robotham, J. L. Endothelin causes portal and pulmonary hypertension in porcine endotoxemic shock. Am. J. Physiol., 272, H1239-1249. (1997)
45. Hammerschmidt, D. E., Hudson, L. D., Weavér, L. J., Craddock, P. R. and Jacob, H. S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Lancet, May 3, 947-949. (1980)
46. Hammerschmidt, D. E. In: Complement in Health and Disease, (ed. Whaley, K.), pp. 267-287. MTP Press, Lancester/Boston. (1986)
47. Levine, S. J., Walsh, T. J., Martinez, A., Eichacker, P. Q., Lopez-Berstein, G. and Natanson, C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Annals Int. Med., 114, 664-666. (1991)
48. Laing, R. B. S., Milne, L. J. R., Leen, C. L. S., Malcolm, G. P. and Steers, A. J. W. Anaphylactic reactions to liposomal amphotericin. Lancet, 344, 682. (1994)
49. Ringdén, O., Andström, E., Remberger, M., Svahn, B. M. and Tollemar, J. Allergic reactions and other rare side effects of liposomal amphotericin. Lancet, 344, 1156-1157. (1994)
50. de Marie, S. Liposomal and lipid-based formulations of amphotericin B. Leukemia, 10, Suppl. 2, S93-S96. (1996)
51. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M. and Gabizon, A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol., 13, 1777-85. (1995)
52. Dezube, B. In: Doxil® Clinical Series, Vol. 1, No. 2. Sequus Pharmaceuticals Inc., Menlo Park, CA. (1996)
53. Alberts, D. S. and Garcia, D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs, 54, Suppl. 4, 30-45. (1997)
54. Weisman, H. F., Bartow, T., Leppo, M. K., Marsh, H. C. J., Carson, G. R., Concino, M. F., Boyle, M. P., Roux, K. H., Weisfeldt, M. L. and Fearon, D. T. Soluble complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science, 249, 146-151. (1990)
55. Cheung, A. K., Parker, C. J. and Hohnholt, M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int., 46, 1680-7. (1994)
56. Smith, E. d., Griswold, D. E., Egan, J. W., Hillegass, L. M., Smith, R. A., Hibbs, M. J. and Gagnon, R. C. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Eur. J. Pharmacol., 236, 477-81. (1993)
57. Gillinov, A. M., DeValeria, P. A., Winkelstein, J. A., Wilson, I., Curtis, W. E., Shaw, D., Yeh, C. G., Rudolph, A. R., Baumgartner, W. A. and Herskowitz, A. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann. Thorac. Surg., 55, 619-24. (1993)
58. Dickneite, G. In: Weir's Handbook of Experimental Immunology. (eds. Herzenberg, L.A., Herzenberg, L.A. & Blackwell, C.), pp. 218.1-218.7. Blackwell Science, Cambridge. (1996)
59. Cable, D. G., Hisamochi, K. and Schaff, H. V. Complement mediates attenuation of endothelium-dependent relaxations in canine coronary arteries after porcine serum exposure: a mechanism for vascular thrombosis in xenograft hyperacute rejection. Circulation, 96 (9 Suppl), II-II5863. (1997)
60. Lennon, P. F., Collard, C. D., Morrissey, M. A. and Stahl, G. L. Complement-induced endothelial dysfunction in rabbits: mechanisms, recovery, and gender differences. Am. J. Physiol., 270, H1924-H1932. (1996)
61. Pierson, R. r. and Parker, R. E. Thromboxane mediates pulmonary vasoconstriction and contributes to cytotoxicity in pig lungs perfused with fresh human blood. Transplant. Proc., 28, 625. (1996)
62. Rinder, C. S., Rinder, H. M., Smith, B. R., Fitch, J. C. K., Smith, J. M. J., Tracey, B., Matis, L. A., Squinto, S. P. and Rollins, S. A. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J. Clin. Invest., 96, 1564-1572. (1995)
63. Shibamoto, T., Wang, H. G., Yamaguchi, Y., Hayashi, T., Saeki, Y., Tanaka, S. and Koyama, S. Effects of thromboxane A2 analogue on vascular resistance distribution and permeability in isolated blood-perfused dog lungs. Lung, 173, 209-21. (1995)
64. Thies, S. D., Corbin, R. S., Goff, C. D., Binns, O. A., Buchanan, S. A., Shockey, K. S., Frierson HF, J. R., Young, J. S., Tribble, C. G. and Kron, I. L. Thromboxane receptor blockade improves oxygenation in an experimental model of acute lung injury. Ann. Thorac Surg., 61, 1453-7. (1996)